430 related articles for article (PubMed ID: 35567571)
21. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
[No Abstract] [Full Text] [Related]
22. DNA Damage Repair Inhibitor for Breast Cancer Treatment.
Min A; Lee KH; Im SA
Adv Exp Med Biol; 2021; 1187():159-179. PubMed ID: 33983578
[TBL] [Abstract][Full Text] [Related]
23. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
Rabenau K; Hofstatter E
Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
[TBL] [Abstract][Full Text] [Related]
24.
Rafiei S; Fitzpatrick K; Liu D; Cai MY; Elmarakeby HA; Park J; Ricker C; Kochupurakkal BS; Choudhury AD; Hahn WC; Balk SP; Hwang JH; Van Allen EM; Mouw KW
Cancer Res; 2020 Jun; 80(11):2094-2100. PubMed ID: 32127357
[TBL] [Abstract][Full Text] [Related]
25. Recruitment of KMT2C/MLL3 to DNA Damage Sites Mediates DNA Damage Responses and Regulates PARP Inhibitor Sensitivity in Cancer.
Chang A; Liu L; Ashby JM; Wu D; Chen Y; O'Neill SS; Huang S; Wang J; Wang G; Cheng D; Tan X; Petty WJ; Pasche BC; Xiang R; Zhang W; Sun P
Cancer Res; 2021 Jun; 81(12):3358-3373. PubMed ID: 33853832
[TBL] [Abstract][Full Text] [Related]
26. Molecular Targeted Therapy in Oncology Focusing on DNA Repair Mechanisms.
Garzón-Hernández C; Ramírez-Merino N; Soberon MCM
Arch Med Res; 2022 Dec; 53(8):807-817. PubMed ID: 36460545
[TBL] [Abstract][Full Text] [Related]
27. Radiotherapy-Poly(ADP-ribose) Polymerase Inhibitor Combinations: Progress to Date.
Derby SJ; Chalmers AJ; Carruthers RD
Semin Radiat Oncol; 2022 Jan; 32(1):15-28. PubMed ID: 34861992
[TBL] [Abstract][Full Text] [Related]
28. Polymerase θ Coordinates Multiple Intrinsic Enzymatic Activities during DNA Repair.
Zahn KE; Jensen RB
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573292
[TBL] [Abstract][Full Text] [Related]
29. An insight into understanding the coupling between homologous recombination mediated DNA repair and chromatin remodeling mechanisms in plant genome: an update.
Banerjee S; Roy S
Cell Cycle; 2021 Sep; 20(18):1760-1784. PubMed ID: 34437813
[TBL] [Abstract][Full Text] [Related]
30. Combination DNA Damage Response (DDR) Inhibitors to Overcome Drug Resistance in Ovarian Cancer.
Nasioudis D; George EM; Xu H; Kim H; Simpkins F
Cancer Treat Res; 2023; 186():189-206. PubMed ID: 37978137
[TBL] [Abstract][Full Text] [Related]
31. Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment.
Genta S; Martorana F; Stathis A; Colombo I
Crit Rev Oncol Hematol; 2021 Dec; 168():103539. PubMed ID: 34800653
[TBL] [Abstract][Full Text] [Related]
32. Triumphs and challenges in exploiting poly(ADP-ribose) polymerase inhibition to combat triple-negative breast cancer.
Wooten J; Mavingire N; Damar K; Loaiza-Perez A; Brantley E
J Cell Physiol; 2023 Aug; 238(8):1625-1640. PubMed ID: 37042191
[TBL] [Abstract][Full Text] [Related]
33. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
34. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
[TBL] [Abstract][Full Text] [Related]
35. Targeting DNA Damage Response in Prostate and Breast Cancer.
Wengner AM; Scholz A; Haendler B
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33158305
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response.
Francica P; Rottenberg S
Genome Med; 2018 Dec; 10(1):101. PubMed ID: 30593284
[TBL] [Abstract][Full Text] [Related]
37. DNA damage response pathways in tumor suppression and cancer treatment.
Liang Y; Lin SY; Brunicardi FC; Goss J; Li K
World J Surg; 2009 Apr; 33(4):661-6. PubMed ID: 19034564
[TBL] [Abstract][Full Text] [Related]
38. Roles of DNA damage repair and precise targeted therapy in renal cancer (Review).
Lai Y; Li Z; Lu Z; Zheng H; Chen C; Liu C; Yang Y; Tang F; He Z
Oncol Rep; 2022 Dec; 48(6):. PubMed ID: 36263616
[TBL] [Abstract][Full Text] [Related]
39. Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2
Biegała Ł; Gajek A; Szymczak-Pajor I; Marczak A; Śliwińska A; Rogalska A
Sci Rep; 2023 Dec; 13(1):22659. PubMed ID: 38114660
[TBL] [Abstract][Full Text] [Related]
40. DNA Damage Repair Inhibitors-Combination Therapies.
Smith G; Alholm Z; Coleman RL; Monk BJ
Cancer J; 2021 Nov-Dec 01; 27(6):501-505. PubMed ID: 34904813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
